Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px
Document › Details

OMass Technologies Ltd.. (7/11/18). "Press Release: OMass Technologies Announces Publication Demonstrating the Impact of Lipid Interactions on GPCR Signalling in Nature". Oxford.

Organisations Organisation OMass Technologies Ltd.
  Today OMass Therapeutics Ltd.
  Group OMass Therapeutics Ltd.
  Organisation 2 University of Oxford
Products Product mass spectrometry (MS)
  Product 2 structure-based drug design
Person Person Robinson, Carol (Univ Oxford 201004 Physical and Theoretical Chemistry Laboratory + OMass)
     


OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today announced the publication of an article in Nature describing the involvement of lipid molecules in G-protein-coupled receptors (GPCR signalling). The study was led by Dr Hsin-Yung Yen, CSO of OMass Technologies and performed in collaboration with Prof. Dame Carol Robinson’s research group at the University of Oxford.

Dr Hsin-Yung Yen and his co-authors* describe how interactions between GPCRs and G-proteins, which are involved in many physiological processes and are key drug targets, are highly regulated by interactions with specific lipid molecules. Although high-resolution structural information is emerging for GPCRs, the effects of lipids on the receptor’s function are largely unknown. Native mass spectrometry was used to resolve discrete populations of endogenous GPCR-lipid species to understanding their effects on down-stream signalling.

The full manuscript “PtdIns(4,5)P2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling” can be found in the July 2018 issue of Nature – https://www.nature.com/articles/s41586-018-0325-6

OMass specialises in applying state-of-the-art mass spectrometry platforms to characterising intact protein assemblies. By providing both access to technology and expertise through collaborations with world-leading pharmaceutical companies, the company is focussed on studying some of the most challenging protein targets in drug discovery.



Further information:

JW Communications +44 (0)7818430877
Julia Wilson juliawilsonuk@gmail.com


Notes for Editors:


About OMass Therapeutics

OMass Therapeutics is a private biopharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com.


* Hsin-Yung Yen, Kin Kuan Hoi, Idlir Liko, George Hedger, Michael R. Horrell, Wanling Song, Di Wu, Philipp Heine, Tony Warne, Yang Lee, Byron Carpenter, Andreas Plückthun, Christopher G. Tate, Mark S. P. Sansom & Carol V. Robinson

   
Record changed: 2018-11-28

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

More documents for OMass Therapeutics Ltd.


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top